A crossover study of triptorelin and leuprorelin acetate.
OBJECTIVE
To compare the potency, side effects, and duration of action of triptorelin and leuprorelin acetate after i.m. injections.


METHODS
Prospective, double-blind crossover clinical study.


METHODS
A teaching hospital.


METHODS
Fifty-four patients with pelvic endometriosis.


METHODS
Twenty-seven patients had three doses of i.m. triptorelin (3.75 mg) followed by three doses of i.m. leuprorelin acetate at 4-week intervals. Twenty-one patients had three doses of i.m. leuprorelin acetate (3.75 mg) followed by three doses of i.m. triptorelin, also at 4-week intervals.


METHODS
Menopausal symptoms, time taken for menstruation to return, serum E(2), FSH, LH levels, lipid profiles, and liver function tests.


RESULTS
The potencies of triptorelin and leuprorelin acetate in lowering the serum E(2), FSH, and LH levels were comparable. The severity of menopausal symptoms, changes in the lipid profile and liver function parameters were similar after triptorelin and leuprorelin acetate. The resurgence of ovarian activities and the spontaneous return of menstruation occurred significantly earlier after leuprorelin acetate than triptorelin.


CONCLUSIONS
Both drugs are equally potent in down-regulating the pituitary-ovarian function, and their side effects are similar. Triptorelin has a longer duration of drug action and can be administered over a longer interval period.
Cheung
T K
TK
Deprtment of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, China. thcheung@cuhk.edu.hk
Lo
K W
KW
Lam
C W
CW
Lau
W
W
Lam
P K
PK
D000328:Adult; D004311:Double-Blind Method; D004715:Endometriosis / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008598:Menstruation; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000009:adverse effects / Q000627:therapeutic use*
D017329:Triptorelin Pamoate; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide